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ABSTRACT
The incidence of melanoma continues to rise globally and is increasing at a rate 
greater than any other cancer. To systematically search for new genes involved in 
melanomagenesis, we collated exome sequencing data from independent melanoma 
cohort datasets, including those in the public domain. We identified recurrent 
mutations that may drive melanoma growth, survival or metastasis, and which may 
hold promise for the design of novel therapies to treat melanoma. These included 
a frequent recurrent (i.e. hotspot) mutation in the 5’ untranslated region of RPS27 
in ~10% of samples. We show that the mutation expands the 5’TOP element, a 
motif known to regulate the expression of most of the ribosomal protein family, to 
which RPS27 belongs, and thus might sensitize the mutated transcript to growth-
mediated regulation. This finding highlights not only the important role of non-protein 
coding genetic aberrations in cancer development but also their potential as novel 
therapeutic targets.
INTRODUCTION
Melanoma is the deadliest form of human skin 
cancer, accounting for 70% of skin cancer related deaths, 
with approximately 48,000 fatalities annually worldwide 
[1,2]. Candidate gene analyses have been powerful in 
identifying mutations, such as BRAF V600E, which has 
become a successful target for the FDA-approved inhibitor, 
vemurafenib. However, approximately 50% of patients do 
not harbor the mutation and some patients with a BRAF 
mutation do not respond to the drug, or quickly acquire 
resistance. As such, there is a strong focus to improve the 
therapeutic strategies for late-stage melanoma. Current 
approaches include the investigation of various drug 
combinations, scheduling and dosage regimens, and the 
development of new therapeutics through the identification 
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of novel drug targets [6-12]. Recent large scale exome and 
genome sequencing studies have rapidly expanded the 
known genetic drivers involved in melanomagenesis [13-
25] Despite this, it is likely a number of additional driver 
genes have yet to be discovered as scaling genetic studies 
with larger sample sizes will reveal novel genes mutated 
at clinically important but lower frequencies [26]. Here, 
we have used a systematic approach to identify additional 
candidate melanoma genes in an unbiased fashion.
RESULTS
One way to identify driver mutations is to look 
for those that are recurrent across multiple samples. 
Recently, several next generation sequencing studies 
have been published on melanoma. We have utilized the 
somatic mutation data from 4 of these studies as well 
as unpublished data we have generated (Supplementary 
Figure 1). The merging of these datasets substantially 
increased the number of samples available to review, 
thus increasing the chances of identifying low frequency 
recurrent mutations. As the published studies were all 
performed at different times and used different procedures 
to annotate their variants, several steps had to be applied to 
get the data into the same format. In some cases the data 
needed to be converted to the more recent genomic build 
(hg19) and redundant samples needed to be removed. 
Once a list of mutations was established from each study, 
the positional data and changes were formatted and 
annotated using the web-based version of oncotator (http://
www.broadinstitute.org/oncotator). Many of these studies 
assessed a combination of both fresh tissue and cell line 
samples of various melanoma subtypes, however as the 
focus of our study was on cutaneous malignant melanoma, 
the subtypes of acral, mucosal and uveal melanoma were 
removed from the newly annotated data. We also removed 
any samples where the initial publication did not include 
a matched normal sample. The resulting output left 246 
metastatic melanoma samples and their annotated somatic 
mutation data to review (Supplementary Table 1).
We limited the scope of our investigation to 178 
mutations occurring at the same chromosomal position 
in 4 or more of the 246 samples (Supplementary Table 
2). As expected, this list included well documented 
frequent oncogenic drivers of melanoma, including 
hotspot mutations in BRAF, NRAS, RAC1, PPP6C, 
TRRAP, MAP3K5 and BCL2L12 [5, 17, 27-29]. Of the 
178 mutations, 136 are missense, 4 are nonsense, 21 are 
silent and 17 occur in 5’ UTRs or within splicing regions 
(Supplementary Table 2).
Of the 178 hotspot mutations identified in the 
collated next-generation sequencing dataset, we prioritized 
those that most frequently appeared, occurring in 5 
or more samples, or which occurred at least 4 times in 
genes with a previous association with tumorigenesis. We 
excluded known hotspot mutations in BRAF, NRAS, RAC1, 
BCL2L12, PPP6C, TRRAP, and MAP3K5 from further 
analysis since these have been thoroughly investigated. 
To validate the mutations and more accurately determine 
prevalence rates, we screened these new candidate 
hotspots in a validation panel that consisted of up to 489 
melanoma cell lines or tumors (Supplementary Table 3). 
Of these, 234 had matching normal DNA that enabled us 
to unambiguously determine somatic mutation status.
A total of 64 mutations were selected for follow up 
screening using the Sequenom MassARRAY® system 
(Supplementary Table 4). Three of these failed the design 
process or could not be validated by Sanger sequencing, 
most likely as a result of these mutations being false 
positive calls in the exome data due to repetitive regions 
of the genome. Eventually, 61 mutations were screened in 
489 samples (Supplementary Table 5). Mutation detection 
was determined using a minimum 10% threshold of the 
mutant allele peak and were all reviewed manually.
From our validation results, the mutation seen at 
the highest frequency was RPS27 (47 of 489, or 9.6%) 
(Table 1 and Supplementary Table 6). Furthermore, we 
screened a panel of 34 cell lines of various tumor types 
(Supplementary Table 7 and Supplementary Table 8); 
however no mutations were identified, suggesting the 
mutation might be specific to melanoma.
The recurrent mutation in the RPS27 gene is located 
in the 5’UTR at position Chr1:153963239 and results 
in a cytidine to thymidine change. According to the 
Data Base of Transcriptional Start Site (DBTSS, http://
dbtss.hgc.jp), this position is the major transcriptional 
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start site of the RPS27 gene. Comparable to most genes 
in the family of ribosomal proteins, RPS27 harbors a 
5’ terminal oligopyrimidine (5’TOP) tract, which is 
required for the translational control of the protein in a 
growth-dependent manner [30]. It has been shown that 
for effective translational regulation, the 5’TOP element 
must begin with a cytidine residue at the 5’ terminus of 
the mRNA, followed by an uninterrupted stretch of 4 to 
15 pyrimidines [31]. Moreover, a single substitution of 
cytidine with uridine, at the cap position is sufficient to 
abolish the translational control of the 5’TOP element 
[32]. The recurrent mutation in the RPS27 gene changes 
the cytidine at the cap site with a thymidine (Figure 1A). 
In case the transcription start site (TSS) is not altered, the 
mutation would abolish the translational regulation of 
the 5’TOP element in the mutated allele. Therefore, we 
studied the effect of the recurrent mutation on the TSS 
of the gene. We performed rapid amplification of cDNA 
ends (RACE) by ligating a RNA linker to the 5’ terminus 
of the mRNAs (Figure1B) to map the TSS. According to 
the results (Figure 1C), the recurrent mutation alters the 
TSS so that it initiates from a cytidine located at position 
Chr1:153963238. As a result, the 5’TOP element was 
not abolished but rather the pyrimidine stretch became 
longer, from 5 to 6 nucleotides (CTTTCC to CTTTTCC, 
respectively).
DISCUSSION
Our comparative analysis of several next generation 
sequencing studies retrieved a novel recurrent mutation 
located at the TSS of the RPS27 gene in ~10% of the 
melanoma cases. The RPS27 gene is overexpressed in 
several malignancies, including melanoma [33, 34]. 
Moreover, RPS27 is known to be involved in growth 
regulation and carcinogenesis [35, 36]. One of the 
signaling pathways that regulates 5’TOP bearing mRNA is 
the mTOR pathway, which is activated by growth factors 
and selectively inhibited by Rapamycin [30]. Previous 
studies have shown that mTOR is highly activated in 
the majority of melanoma cases and is associated with 
poorer prognosis characteristics of the disease [37,38]. 
In addition, it has been indicated that the length of the 
pyrimidine stretch of the 5’TOP element may affect its 
translational regulation efficiency [39, 40]. In light of these 
results and the RACE data presented in this study, we 
Figure 1: The RPS27 recurrent mutation alters the transcription starting site (TSS) of the RPS27 gene. A. Description 
of the genomic sequence flanking the recurrent mutation of the RPS27 gene. The 5’TOP element sequence is underlined. To determine the 
effect of the C > T recurrent mutation on the TSS of the RPS27 gene, RACE analysis was performed using the RNA linker described in 
B. cDNA was prepared from the ligated mRNA and amplified using a Forward primer located in the linker and a RPS27 specific Reverse 
primer. The amplified products were cloned in pGEM-T easy vector. Colonies were picked and sequenced. A representative chromatography 
and the genomic sequence of the 5’ terminus of the transcripts is described in C. The 5’TOP element is underlined, the TSS is designated 
with arrows and the C > T substitution is highlighted with red. WT: wild-type; mut: mutant.
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hypothesize that the mutation in the RPS27 5’UTR would 
promote the expression of the gene upon the induction of 
mTOR, which may contribute to the progression and/or 
the viability of the malignant cells.
In summary, this is the first study to demonstrate 
that melanoma patients harbor mutations in RPS27. At 
a mutation rate of ~10%, RPS27 is ranked as the fourth 
most frequent gene with recurrent mutations identified in 
melanoma (ranked order: TERT, BRAF, NRAS, RPS27, 
RAC1). Functional studies of the effect of the recurrent 
mutation are ongoing. Yet, due to the high frequency of the 
mutation, we hypothesize that RPS27 is a bona-fide driver 
of melanoma development.
MATERIALS AND METHODS
Data formatting
All mutational data from 6 different whole exome/
genome sources was collated, 4 published studies [13, 18, 
28, 29] as well as unpublished data. The data was first 
formatted to so that all positional data was mapped to the 
same genome build. In this case any data that was on hg18 
was lifted over to hg19 using the Lift Genome Annotations 
tool available from UCSC (http://genome.ucsc.edu/cgi- 
bin/hgLiftOver). In some situations with the merging 
of data it became necessary to eliminate redundant 
information. For instance, with some samples both a tumor 
and a cell line derived from it were sequenced in which 
case the majority of the mutations were shared. This is 
also true in the case of samples shared between studies 
[28] as well as the multiple metastases extracted from 
the same patient in another study [18]. When removing 
these duplicates all mutations were retained at a count of 
one and the sample name was merged into a single entry. 
This step was taken to ensure that the number of recurrent 
positions was not inflated in later analysis. Once this list of 
mutations was established, the positional data and changes 
were formatted to an oncotator input format and annotated 
using the web-based version of oncotator (http://www.
broadinstitute.org/oncotator). The next step taken was to 
remove any samples that were listed as acral, mucosal or 
uveal melanoma subtypes as the focus of this study was 
on cutaneous melanoma. In the final step we also removed 
any samples where the initial publication did not include 
a matched normal genotype. This left us with a list of 246 
samples to investigate.
Validation screen
Mutation detection was performed using the 
Sequenom MassARRAY® system following standard 
protocols and assays were designed using the Sequenom 
Assay Design suite online (Sequenom, San Diego). In 
brief, 20 ng of genomic DNA were used in a PCR reaction 
and cleaned post-amplification with shrimp alkaline 
phosphatase. A single base pair extension reaction using 
iPLEX Pro chemistry was performed, resin-treated to 
remove contaminants and spotted onto SpectroCHIP 
II arrays. Mutant and wild type alleles were then 
discriminated via mass spectrometry using the Sequenom 
MassARRAY® Analyser 4 platform. Mutations were 
detected using a minimum 10% threshold of the mutant 
allele peak and were all manually reviewed. The oligos 
used for the PCR, the extension stages and a BLAT 
analysis confirming that the amplified region is unique for 
RPS27 gene are described in supplementary figure 2.
Rapid Amplification of cDNA Ends (RACE) assay
Total RNA was extracted from 39T cells harboring 
the RPS27mutation using an RNeasy kit (Qiagen) 
according to the manufacturer instructions. RACE assay 
was performed using a GeneRacerTM Kit (Invitrogen). 
Briefly, 7 µg of total RNA were dephosphorylated 
using Shrimp Alkaline Phosphatase (New England, 
BioLabs). Then the sample was subjected to tobacco 
acid pyrophosphates (epicenter). An RNA linker with the 
sequence 5’:CGACUGGAGCACGAGGACACUGACA 
UGGACUGAAGGAGUAGAAA was ligated to the 
5’ terminus of the mRNA using T4 RNA Ligase (New 
England, BioLabs). cDNA was prepared with a RSP27 
gene specific oligo 5’: AGTGCTGCTTCCTCCTGAAG 
using AMV reverse transcriptase, native (EURx). 
cDNA template was amplified with Platinume Taq DNA 
polymerase (Invitrogen) using the following primers: 
Forward 5’ GGACACTGACATGGACTGAAGGAGTA
,Reverse 5’ CGTTTGTGCATGGCTAAAGA. The PCR 
products were cloned into the pGEM-T Easy vector. 
Colonies were picked and sequenced. Sequencing results 
were analyzed using Mutation Surveyor V3.10.
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